Latest & greatest articles for hepatitis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hepatitis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hepatitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hepatitis

1. Chronic hepatitis B virus infection.

Chronic hepatitis B virus infection. Chronic hepatitis B virus infection is a global public health threat that causes considerable liver-related morbidity and mortality. It is acquired at birth or later via person-to-person transmission. Vaccination effectively prevents infection and chronic hepatitis B virus carriage. In chronically infected patients, an elevated serum hepatitis B virus DNA concentration is the main risk factor for disease progression, although there are other clinical (...) and viral parameters that influence disease outcomes. In addition to liver biochemistry, virological markers, and abdominal ultrasonography, non-invasive assessment of liver fibrosis is emerging as an important assessment modality. Long-term nucleos(t)ide-analogue therapy is safe and well tolerated, achieves potent viral suppression, and reduces the incidence of liver-related complications. However, a need to optimise management remains. Promising novel therapies are at the developmental stage

Lancet2018

4. Harm reduction approaches predicted to reduce rates of new hepatitis C infection for people who inject drugs

Harm reduction approaches predicted to reduce rates of new hepatitis C infection for people who inject drugs Signal - Harm reduction approaches predicted to reduce rates of new hepatitis C infection for people who inject drugs Dissemination Centre Discover Portal NIHR DC Discover Harm reduction approaches predicted to reduce rates of new hepatitis C infection for people who inject drugs Published on 5 December 2017 A combination of providing clean needles and syringes and offering safer oral (...) therapy, such as methadone, reduced the predicted risk of becoming infected with hepatitis C virus by 71%. Providing both services to people who inject drugs was likely to be cost-effective and has the potential to be cost-saving in some parts of the UK, depending on the size of the local population of people who inject drugs and underlying rates of infection. Current services are estimated to save up to £54 million in costs of treating hepatitis C infection. This is in addition to the savings made

NIHR Dissemination Centre2018

5. Tenofovir reduces mother-to-child hepatitis B transmission

Tenofovir reduces mother-to-child hepatitis B transmission Signal - Tenofovir reduces mother-to-child hepatitis B transmission Dissemination Centre Discover Portal NIHR DC Discover Tenofovir reduces mother-to-child hepatitis B transmission Published on 25 July 2017 Giving pregnant women with hepatitis B the drug tenofovir reduced the likelihood of passing the infection on to their baby by about 80% and did not have any adverse impact on mother or child. Hepatitis B often doesn't cause any (...) obvious symptoms in adults and typically passes in a few months without treatment, but in children it often persists for years and may cause progressive liver damage with cirrhosis and increased risk of liver cancer. Babies can get the infection from their mother during birth. The findings of this systematic review support current NICE recommendations that pregnant women with active hepatitis B infection are treated in the third trimester using the drug tenofovir and at risk babies immunised after

NIHR Dissemination Centre2018

6. VAXELIS, hexavalent vaccine against diphtheria, tetanus, poliomyelitis, pertussis, Haemophilus influenzae type b infections, hepatitis B

VAXELIS, hexavalent vaccine against diphtheria, tetanus, poliomyelitis, pertussis, Haemophilus influenzae type b infections, hepatitis B Haute Autorité de Santé - VAXELIS, vaccin hexavalent contre diphtérie, tétanos, poliomyélite, coqueluche, infections à Haemophilus influenzae type b, hépatite B Développer la qualité dans le champ sanitaire, social et médico-social Recherche Évaluation & Recommandation La HAS Accréditation & Certification Outils, Guides & Méthodes Agenda Avis sur les

Haute Autorite de sante2018

7. Randomized clinical trial of stapler hepatectomy versus LigaSure transection in elective hepatic resection

Randomized clinical trial of stapler hepatectomy versus LigaSure transection in elective hepatic resection 30069876 2018 08 02 1365-2168 105 9 2018 Aug The British journal of surgery Br J Surg Randomized clinical trial of stapler hepatectomy versus LigaSure™ transection in elective hepatic resection. 1119-1127 10.1002/bjs.10902 Previous studies have demonstrated stapler hepatectomy and use of various energy devices to be safe alternatives to the clamp-crushing technique in elective hepatic (...) resection. In this randomized trial, the effectiveness and safety of stapler hepatectomy were compared with those of parenchymal transection with the LigaSure™ vessel sealing system. Patients scheduled for elective liver resection at two tertiary-care centres were randomized during surgery to stapler hepatectomy or transection with the LigaSure™ device. Total intraoperative blood loss was the primary efficacy endpoint. Transection time, duration of operation, perioperative complications and length

EvidenceUpdates2018

8. Twelve-Month Outcomes After Transplant of Hepatitis C-Infected Kidneys Into Uninfected Recipients: A Single-Group Trial.

Twelve-Month Outcomes After Transplant of Hepatitis C-Infected Kidneys Into Uninfected Recipients: A Single-Group Trial. Background: Organs from hepatitis C virus (HCV)-infected deceased donors are often discarded. Preliminary data from 2 small trials, including THINKER-1 (Transplanting Hepatitis C kidneys Into Negative KidnEy Recipients), suggested that HCV-infected kidneys could be safely transplanted into HCV-negative patients. However, intermediate-term data on quality of life and renal (...) participants achieved HCV cure. Hepatic and renal complications were transient or were successfully managed. Mean PCS and MCS quality-of-life scores decreased at 4 weeks; PCS scores then increased above pretransplant values, whereas MCS scores returned to baseline values. Estimated GFRs were similar between THINKER participants and matched recipients of HCV-negative kidneys at 6 months (median, 67.5 vs. 66.2 mL/min/1.73 m2; 95% CI for between-group difference, -4.2 to 7.5 mL/min/1.73 m2) and 12 months

Annals of Internal Medicine2018

9. Corticosteroids Reduce Risk of Death Within 28 Days for Patients With Severe Alcoholic Hepatitis, Compared With Pentoxifylline or Placebo-a Meta-analysis of Individual Data From Controlled Trials

Corticosteroids Reduce Risk of Death Within 28 Days for Patients With Severe Alcoholic Hepatitis, Compared With Pentoxifylline or Placebo-a Meta-analysis of Individual Data From Controlled Trials 29738698 2018 08 13 2018 08 13 1528-0012 155 2 2018 08 Gastroenterology Gastroenterology Corticosteroids Reduce Risk of Death Within 28 Days for Patients With Severe Alcoholic Hepatitis, Compared With Pentoxifylline or Placebo-a Meta-analysis of Individual Data From Controlled Trials. 458-468.e8 S0016 (...) -5085(18)34495-0 10.1053/j.gastro.2018.05.011 We performed a meta-analysis of individual patient data from 11 randomized controlled trials comparing corticosteroids, pentoxifylline, or their combination in patients with severe alcoholic hepatitis. We compared the effects of the treatments on survival for 28 days or 6 months, and response to treatment based on the Lille model. We searched PubMed for randomized controlled trials of pharmacologic therapy for severe alcoholic hepatitis. Our final

EvidenceUpdates2018

10. Hepatitis

Hepatitis Top results for hepatitis - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for hepatitis The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

12. Transplanting Hepatitis C Virus-Infected Versus Uninfected Kidneys Into Hepatitis C Virus-Infected Recipients: A Cost-Effectiveness Analysis.

Transplanting Hepatitis C Virus-Infected Versus Uninfected Kidneys Into Hepatitis C Virus-Infected Recipients: A Cost-Effectiveness Analysis. Background: Direct-acting antiviral agents are now available to treat chronic hepatitis C virus (HCV) infection in patients with end-stage renal disease (ESRD). Objective: To examine whether it is more cost-effective to transplant HCV-infected or HCV-uninfected kidneys into HCV-infected patients. Design: Markov state-transition decision model. Data

Annals of Internal Medicine2018

13. Two drug treatments for severe alcoholic hepatitis do not improve survival rates

Two drug treatments for severe alcoholic hepatitis do not improve survival rates Signal - Two drug treatments for severe alcoholic hepatitis do not improve survival rates Dissemination Centre Discover Portal NIHR DC Discover Two drug treatments for severe alcoholic hepatitis do not improve survival rates Published on 23 April 2015 This NIHR funded trial found that neither prednisolone nor pentoxifylline improved mortality for people with severe alcoholic hepatitis. No differences were found (...) in mortality at 28 or 90 days, or in the need for liver transplant at one year. Overall mortality was high. Nearly three in ten people died before 90 days and more than half (56%) at one year. This shows that other new treatments are needed and more needs to be done to encourage complete abstinence from alcohol following severe alcoholic hepatitis. Share your views on the research. Why was this study needed? UK estimates from 2009 show a quarter of adults drink in a hazardous or harmful way. People

NIHR Dissemination Centre2018

14. Hepatitis C

Hepatitis C Autosynthesis - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button

Trip Evidence Maps2018

15. Hepatitis B

Hepatitis B Autosynthesis - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button

Trip Evidence Maps2018

17. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection

Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection 29535028 2018 06 03 1528-0012 154 8 2018 Jun Gastroenterology Gastroenterology Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection. 2111-2121.e8 S0016-5085(18)30314-7 10.1053/j.gastro.2018.03.022 Treatment with direct-acting antiviral (DAA) agents can reduce Model (...) for End-Stage Liver Disease and Child-Pugh-Turcotte (CPT) scores in patients with decompensated cirrhosis caused by hepatitis C virus. However, many of these patients still die or require liver transplantation. We collected data on baseline features of patients and aimed to develop a scoring system to predict response to DAA therapy. We performed a retrospective analysis of data from 4 trials on the effects of sofosbuvir-based therapy in patients with hepatitis C virus-associated decompensated

EvidenceUpdates2018

18. Ledispavir / sofosbuvir (Harvoni) - treatment of chronic hepatitis C (CHC) in adolescents

Ledispavir / sofosbuvir (Harvoni) - treatment of chronic hepatitis C (CHC) in adolescents Abbreviated Submission ledipasvir/sofosbuvir 90mg/400mg film-coated tablet (Harvoni ® ) SMC No 1343/18 Gilead Sciences 4 May 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission (...) ledipasvir/sofosbuvir (Harvoni ® ) is accepted for restricted use within NHS Scotland. Indication under review: treatment of chronic hepatitis C (CHC) in adolescents aged 12 to <18 years. SMC restriction: genotype 1 and 4 CHC only. SMC has previously accepted ledipasvir/sofosbuvir for use in adults with genotype 1 and 4 CHC. Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice represents the view of the Scottish Medicines Consortium

Scottish Medicines Consortium2018

19. Glecaprevir/pibrentasvir (Maviret) - chronic hepatitis C virus (HCV)

Glecaprevir/pibrentasvir (Maviret) - chronic hepatitis C virus (HCV) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Summary Basis of Decision (SBD) for Contact: Summary basis of decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent activity SBDs written for approved after September 1

Health Canada - Drug and Health Product Register2018

20. Vosevi - for the treatment of chronic hepatitis C virus (HCV) infection

Vosevi - for the treatment of chronic hepatitis C virus (HCV) infection Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Summary Basis of Decision (SBD) for Contact: Summary basis of decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent activity SBDs written for approved after September 1

Health Canada - Drug and Health Product Register2018